Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Gelijkaardige items

• Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771
  door: Gray, Michael, et al.
  Gepubliceerd in: (2015)
• Targeting of phosphatidylserine by monoclonal antibodies reverses an immunosuppressive checkpoint inducing innate and specific anti-tumor responses
  door: Gong, Jian, et al.
  Gepubliceerd in: (2013)
• Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
  door: Gong, Jian, et al.
  Gepubliceerd in: (2014)
• Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment
  door: Yopp, Adam, et al.
  Gepubliceerd in: (2014)
• Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma
  door: Freimark, Bruce D., et al.
  Gepubliceerd in: (2016)